将热疗与传统化疗相结合的腹腔内热化疗(IHCP)渐成治疗恶性肿瘤新方法。热疗与化疗联用可加强化疗药的细胞毒作用,增加药物对癌组织的渗透性。患者行IHCP前尽可能行理想减瘤术,研究表明,IHCP可改善患者的生存率和生活质量,减少化疗毒性,特别对晚期卵巢癌化疗耐药及有腹膜转移患者效果尤为明显。但目前尚无标准化疗方案、药物剂量、灌注速度和灌注液渗透压及灌注持续时间等。对该项技术标准化研究成为热点。 Intraperitoneal chemotherapy (IHCP), a combination of hyperthermia and traditional chemotherapy, is emerging as a new approach to treating malignant tumors. Combination of hyperthermia and chemotherapy can enhance the cytotoxic effect of chemotherapy drugs, increase the permeability of drugs on cancer. Patients before IHCP ideal line reduction surgery, studies have shown that IHCP can improve patient survival and quality of life, reduce the toxicity of chemotherapy, especially for advanced ovarian cancer chemoresistant and peritoneal metastasis in patients with particularly effective. However, there is no standard chemotherapy, drug dosage, perfusion rate and perfusion fluid osmotic pressure and perfusion duration and so on. The standardization of technology research has become a hot spot.